Umberto Pensato on Cancer and Stroke
Umberto Pensato, Assistant Professor of Neurology at the Humanitas University, Research Collaborator at the University of Calgary, shared on LinkedIn:
”Stroke in patients with cancer is common (1 every 7 patients), yet it is becoming extremely challenging to understand patient prognosis and goal-of-care, especially in the time-pressured environment of acute stroke care, resulting in missed/delayed acute treatment (not really in keeping with “Time is Brain”).
This is a call for oncologists, please provide upfront: (i)life expectancy (> or < 6 months?), (ii) goal-of-care (resuscitate, medical or comfort?), and (iii) intent of oncologist treatment (curative or palliative). Help us treat these patients better and faster
Take a look at our viewpoint in JAMA Oncology, Ronda Lun, Jeffrey Q Cao, and Andrew Demchuk, Humanitas University, University of Calgary”
Read the full article here.
Article: Stroke in Patients With Cancer—Time Is Brain
Authors: Ronda Lun, Jeffrey Q Cao, Andrew Demchuk, Umberto Pensato
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 17, 2026, 15:34Folusho Adeosun: Raising Fetal Hemoglobin as a Powerful Protective Shield in Sickle Cell Disease
-
Mar 17, 2026, 15:28Aafreen Kotadiya: Why a Great Blood Bank Team is a Rare and Powerful Asset in Transfusion Medicine
-
Mar 17, 2026, 15:26Nathan Connell: $50 Million Gift to Advance Cell and Gene Therapy at Mass General Brigham
-
Mar 17, 2026, 15:10Peter Zdziarski: Standing Together for Ultra Rare Bleeding Disorders Awareness Day
-
Mar 17, 2026, 14:58Heghine Khachatryan: PFO, Cryptogenic Stroke, and Factor V Leiden – Closure or Lifelong Anticoagulation?
-
Mar 17, 2026, 14:56Mahesan Subramaniam: A Visual Guide to Heart Valve Disease
-
Mar 17, 2026, 14:55Daniel Victor Ortigoza: Apixaban Shows Lower Bleeding Risk than Rivaroxaban in Acute VTE
-
Mar 17, 2026, 14:52Kanishk Kumar: ATTR Amyloidosis Therapeutics Market Poised for a Pipeline Revolution
-
Mar 17, 2026, 14:39Giordano Botta: VA and Allelica Partner on Clinical Study of PRS and PGx in Cardiovascular Prevention